Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Depreciation and Depletion: 2009-2025

Historic Depreciation and Depletion for Aytu Biopharma (AYTU) over the last 12 years, with Sep 2025 value amounting to $100,000.

  • Aytu Biopharma's Depreciation and Depletion changed negligibly% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $400,000, marking a year-over-year decrease of 42.86%. This contributed to the annual value of $200,000 for FY2025, which is 77.78% down from last year.
  • Per Aytu Biopharma's latest filing, its Depreciation and Depletion stood at $100,000 for Q3 2025, which was down 0.00% from $100,000 recorded in Q1 2025.
  • In the past 5 years, Aytu Biopharma's Depreciation and Depletion ranged from a high of $500,000 in Q2 2021 and a low of $100,000 during Q1 2021.
  • Over the past 3 years, Aytu Biopharma's median Depreciation and Depletion value was $150,000 (recorded in 2024), while the average stood at $190,000.
  • As far as peak fluctuations go, Aytu Biopharma's Depreciation and Depletion surged by 2,122.22% in 2021, and later crashed by 66.67% in 2024.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Depreciation and Depletion stood at $400,000 in 2021, then remained steady at $400,000 in 2022, then dropped by 25.00% to $300,000 in 2023, then slumped by 66.67% to $100,000 in 2024, then remained steady at $100,000 in 2025.
  • Its Depreciation and Depletion stands at $100,000 for Q3 2025, versus $100,000 for Q1 2025 and $100,000 for Q4 2024.